Thermo Fisher Scientific is cutting 300 employees across two viral vector manufacturing facilities in Massachusetts, marking ...

GH Research has shared compelling data in people with a traditionally challenging form of depression dosed with its ...

For the first time, the FDA will consider whether to approve a trio of drugs for tiny patient populations based on trials ...

Cystic fibrosis drug developer Sionna Therapeutics hopes to join the IPO wave started by Metsera and Maze Therapeutics last ...

Algiax Pharmaceuticals’ non-opioid candidate has achieved “clinically meaningful” pain reduction in a mid-stage trial of ...

Radiopharmaceuticals biotech AdvanCell has pulled together a $112 million Series C about two years after its much smaller ...

Pfizer’s Braftovi combo regimen helped prolong the lives of certain patients with previously untreated colorectal cancer, and ...

Johnson & Johnson’s subcutaneous form of Rybrevant has been recommended for approval by the European Medicines Agency’s human ...

Tectonic plans $185M private placement after stock swings. Acelyrin returns drug to Affibody. Immunome, 89bio complete offerings. Valneva gets $32.8M DoD contract for Ixiaro vaccine.

De­fine Ven­tures has its eye on around 20 or so health tech star­tups that it thinks will go pub­lic or be bought up over the … ...

Robert F. Kennedy Jr.’s chances of becoming HHS chief likely hinge on one of his more controversial stances: that vaccines ...

Genentech sues federal government over 340B discounts to STD clinics, joining Amgen, Eli Lilly and UCB in challenging program ...